TY  - INPR
A1  - Kim, Yeonsu
A1  - Jacobsen, Henning
A1  - Fuerholzner, Bettina
A1  - Eschke, Kathrin
A1  - Hoffmann, Markus
A1  - Chaudhry, Muhammad Zeeshan
A1  - Bertoglio, Federico
A1  - Hust, Michael
A1  - Widera, Marek
A1  - Ciesek, Sandra
A1  - Pöhlmann, Stefan
A1  - Čičin-Šain, Luka
T1  - Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
T2  - bioRxiv
N2  - Vaccines are central to controlling the coronavirus disease 2019 (COVID-19) pandemic but the durability of protection is limited for currently approved COVID-19 vaccines. Further, the emergence of variants of concern (VoCs) that evade immune recognition has reduced vaccine effectiveness, compounding the problem. Here, we show that a single dose of a murine cytomegalovirus (MCMV)-based vaccine, which expresses the spike (S) protein of the virus circulating early in the pandemic (MCMVS), protects highly susceptible K18-hACE2 mice from clinical symptoms and death upon challenge with a lethal dose of D614G SARS-CoV-2. Moreover, MCMVS vaccination controlled two immune-evading VoCs, the Beta (B.1.135) and the Omicron (BA.1) variants in BALB/c mice, and S-specific immunity was maintained for at least 5 months after immunization, where neutralizing titers against all tested VoCs were higher at 5-months than at 1-month post-vaccination. Thus, cytomegalovirus (CMV)-based vector vaccines might allow for long-term protection against COVID-19.
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/73125
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-731252
IS  - 2022.11.25.517953 Version 1
PB  - bioRxiv
ER  -